10-Q Filing

LifeMD, Inc. CIK: 948320 Q1 2016

Filing Information

Form Type	10-Q
Accession Number	`0001213900-16-013460`
Period End Date	20160331
Filing Date	20160516
Fiscal Year	2016
Fiscal Period	Q1
XBRL Instance	immd-20160331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 37 Income Statement 32 Cash Flow Statement 34 Stockholders Equity 9

Balance Sheet 37 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Cash	`CashAndCashEquivalentsAtCarryingValue`	$75.50K	USD	Point-in-time
Cash	`CashAndCashEquivalentsAtCarryingValue`	$203.62K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	32.01M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	32.01M	shares	Point-in-time
Cash	`CashAndCashEquivalentsAtCarryingValue`	$232.98K	USD	Point-in-time
Trade accounts receivable, net	`AccountsReceivableNetCurrent`	$299.34K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	32.01M	shares	Point-in-time
Trade accounts receivable, net	`AccountsReceivableNetCurrent`	$154.44K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	32.01M	shares	Point-in-time
Inventory, net	`InventoryNet`	$61.05K	USD	Point-in-time
Inventory, net	`InventoryNet`	$138.49K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$641.45K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$448.47K	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$167.48K	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$336.96K	USD	Point-in-time
Notes payable	`NotesPayableCurrent`	$100.00K	USD	Point-in-time
Notes payable	`NotesPayableCurrent`	$100.00K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$436.96K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$267.48K	USD	Point-in-time
Common stock, $0.01 par value; 50,000,000 shares authorized, 32,010,375 shares issued and outstanding	`CommonStockValue`	$320.10K	USD	Point-in-time
Common stock, $0.01 par value; 50,000,000 shares authorized, 32,010,375 shares issued and outstanding	`CommonStockValue`	$320.10K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$8.37M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$8.41M	USD	Point-in-time
Accumulated (deficit)	`RetainedEarningsAccumulatedDeficit`	$-8.59M	USD	Point-in-time
Accumulated (deficit)	`RetainedEarningsAccumulatedDeficit`	$-8.65M	USD	Point-in-time
Total Immudyne, Inc. Stockholders' Equity	`StockholdersEquity`	$100.08K	USD	Point-in-time
Total Immudyne, Inc. Stockholders' Equity	`StockholdersEquity`	$76.90K	USD	Point-in-time
Noncontrolling interests	`MinorityInterest`	$80.91K	USD	Point-in-time
Noncontrolling interests	`MinorityInterest`	$127.59K	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$180.99K	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$204.49K	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$448.47K	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$641.45K	USD	Point-in-time

Income Statement 32 line items

Line Item	Tag	Value	Unit	Period
Net sales	`Revenues`	$1.64M	USD	1 Quarter
Net sales	`Revenues`	$288.28K	USD	1 Quarter
Cost of sales	`CostOfRevenue`	$74.22K	USD	1 Quarter
Cost of sales	`CostOfRevenue`	$1.34M	USD	1 Quarter
Gross Profit	`GrossProfit`	$303.09K	USD	1 Quarter
Gross Profit	`GrossProfit`	$214.06K	USD	1 Quarter
Compensation and related expenses	`CompensationAndRelatedExpenses`	$85.39K	USD	1 Quarter
Compensation and related expenses	`CompensationAndRelatedExpenses`	$240.46K	USD	1 Quarter
Professional fees	`ProfessionalFees`	$69.31K	USD	1 Quarter
Professional fees	`ProfessionalFees`	$35.51K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$98.41K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$85.33K	USD	1 Quarter
Operating (Loss) Income	`OperatingIncomeLoss`	$-105.10K	USD	1 Quarter
Operating (Loss) Income	`OperatingIncomeLoss`	$7.83K	USD	1 Quarter
Interest (expense)	`InterestExpense`	$3.06K	USD	1 Quarter
Interest (expense)	`InterestExpense`	$10.47K	USD	1 Quarter
Net (Loss) Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-2.63K	USD	1 Quarter
Net (Loss) Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-108.16K	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	-	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-4.30K	USD	1 Quarter
Net (Loss) Income	`ProfitLoss`	$1.67K	USD	1 Quarter
Net (Loss) Income	`ProfitLoss`	$-108.16K	USD	1 Quarter
Net (Loss) income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-46.11K	USD	1 Quarter
Net (Loss) income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Net (Loss) income attributable to Immudyne, Inc.	`NetIncomeLoss`	$1.67K	USD	1 Quarter
Net (Loss) income attributable to Immudyne, Inc.	`NetIncomeLoss`	$-62.05K	USD	1 Quarter
Basic and diluted (loss) income per share attributable to Immudyne, Inc.	`EarningsPerShareBasicAndDiluted`	-	USD	1 Quarter
Basic and diluted (loss) income per share attributable to Immudyne, Inc.	`EarningsPerShareBasicAndDiluted`	-	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$30.73M	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$32.01M	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$31.36M	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$32.01M	USD	1 Quarter

Cash Flow Statement 34 line items

Line Item	Tag	Value	Unit	Period
Net Income (Loss)	`ProfitLoss`	$1.67K	USD	1 Quarter
Net Income (Loss)	`ProfitLoss`	$-108.16K	USD	1 Quarter
Depreciation	`Depreciation`	$14.24K	USD	1 Quarter
Depreciation	`Depreciation`	-	USD	1 Quarter
Deferred tax benefit	`DeferredIncomeTaxExpenseBenefit`	-	USD	1 Quarter
Deferred tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-4.30K	USD	1 Quarter
Stock compensation expense	`ShareBasedCompensation`	$38.87K	USD	1 Quarter
Stock compensation expense	`ShareBasedCompensation`	$2.00K	USD	1 Quarter
Trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$144.90K	USD	1 Quarter
Trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$58.48K	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	$2.45K	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	$77.44K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$169.48K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$-22.86K	USD	1 Quarter
Net cash (used) by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-122.16K	USD	1 Quarter
Net cash (used) by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-70.19K	USD	1 Quarter
Investment in subsidiary by noncontrolling interest	`ProceedsFromPaymentsToMinorityShareholders`	-	USD	1 Quarter
Investment in subsidiary by noncontrolling interest	`ProceedsFromPaymentsToMinorityShareholders`	$92.79K	USD	1 Quarter
Increase in notes payable	`IncreaseDecreaseInNotesPayableCurrent`	$100.00K	USD	1 Quarter
Increase in notes payable	`IncreaseDecreaseInNotesPayableCurrent`	-	USD	1 Quarter
Repayment of notes payable	`RepaymentsOfNotesPayable`	$35.26K	USD	1 Quarter
Repayment of notes payable	`RepaymentsOfNotesPayable`	-	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$92.79K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$64.74K	USD	1 Quarter
Net (decrease) in cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-29.36K	USD	1 Quarter
Net (decrease) in cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-5.44K	USD	1 Quarter
Cash at beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$75.50K	USD	Point-in-time
Cash at beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$203.62K	USD	Point-in-time
Cash at beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$232.98K	USD	Point-in-time
Cash at end of the period	`CashAndCashEquivalentsAtCarryingValue`	$75.50K	USD	Point-in-time
Cash at end of the period	`CashAndCashEquivalentsAtCarryingValue`	$203.62K	USD	Point-in-time
Cash at end of the period	`CashAndCashEquivalentsAtCarryingValue`	$232.98K	USD	Point-in-time
Cash paid during the period for interest	`InterestPaid`	$3.06K	USD	1 Quarter
Cash paid during the period for interest	`InterestPaid`	$10.47K	USD	1 Quarter

Stockholders Equity 9 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$180.99K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$204.49K	USD	Point-in-time
Stock based compensation	`ShareBasedCompensation`	$38.87K	USD	1 Quarter
Stock based compensation	`ShareBasedCompensation`	$2.00K	USD	1 Quarter
Investment in subsidiary by noncontrolling interest	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$92.79K	USD	1 Quarter
Net (loss)	`ProfitLoss`	$1.67K	USD	1 Quarter
Net (loss)	`ProfitLoss`	$-108.16K	USD	1 Quarter
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$180.99K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$204.49K	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.